Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cibisatamab + Atezolizumab in CEA-Positive Solid Tumors
NCT02650713Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2016
- Primary completion
- Jan 2020
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 1, open-label trial of cibisatamab in solid tumor (2 arms), sponsored by Roche. Primary endpoints: Number of Participants with Adverse Events, Percentage of Participants with Dose-Limiting Toxicities and 2 more. Started Jan 2016; status: completed.
02
Drugs
cibisatamab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02650713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650713.